|
|
|
| Nutritional therapy of patients with liver cancer in different disease states |
| 1 Weng Min, 1 Dai Zhengyan,2 Wang Kunhua |
| 1
Department of Clinical Nutrition, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China; 2
NHC
Key Laboratory of Drug Addiction Medicine, Kunming 650032, Yunnan, China |
|
|
|
|
Abstract Liver cancer is one of the most common malignant tumor that occurs in digestive system. Liver cancer is the 4th in
morbidity and 2nd in mortality in China, which is a seriously endanger people's health and life. Malnutrition occurs throughout the
entire course of liver cancer and the incidence of malnutrition is 80%. Patients often experience muscle protein consumption and
decreased oxidation of branched amino acids, especially protei⁃energy malnutrition. For the diagnosis of malnutrition, liver cancer
patients need routine nutritional diagnosis (nutrition screening, nutritional assessment and comprehensive assessment) when they are
admitted to hospital, and follow the five⁃step principle for nutrition intervention. Optimal daily energy intake should not be lower than
30-35 kcal/kg, optimal daily protein intake should not be lower than 1.2-1.5 g/kg. For patients with hepatic encephalopathy need to
reduce protein intake as appropriately and select protein sources reasonably. Patients with liver cancer with metabolic disorders and
multiple organ dysfunction require multidisciplinary treatment and adhere to full nutritional management. Liver cancer patients which
undergo liver resection, liver transplantation and interventional treatment have various nutritional problems, also accompanied by liver
cirrhosis, hepatic encephalopathy, sarcopenia and sarcopenic obesity, individualized nutritional therapy in different disease states have
a positive effect on the quality of life and prognosis of liver cancer patients. This article summarizes the nutritional therapy of patients
with liver cancer in different clinical disease states to improve the prognosis of patients with liver cancer.
|
|
Received: 10 October 2021
|
|
|
|
|
|
|
